Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 5—May 2017

Research

Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection

Matthew H. CollinsComments to Author , Eileen McGowan, Ramesh Jadi, Ellen Young, Cesar A. Lopez, Ralph S. Baric, Helen M. Lazear, and Aravinda M. de SilvaComments to Author 
Author affiliations: University of North Carolina, Chapel Hill, North Carolina, USA

Main Article

Figure 1

Binding of DENV immune serum to Zika virus virions. Zika virus and 4 DENV serotypes were captured by using plate-bound mouse monoclonal antibody 4G2 and incubated with serum from donors who had had a primary DENV, secondary DENV, or primary Zika virus infection. In 2 separate experiments (A, B), serum binding was detected by using a horseradish peroxidase–conjugated human IgG. C, D) Differential global binding of each virus was accounted for by subtracting background from native human serum and

Figure 1. Binding of DENV immune serum to Zika virus virions. Zika virus and 4 DENV serotypes were captured by using plate-bound mouse monoclonal antibody 4G2 and incubated with serum from donors who had had a primary DENV, secondary DENV, or primary Zika virus infection. In 2 separate experiments (A, B), serum binding was detected by using a horseradish peroxidase–conjugated human IgG. C, D) Differential global binding of each virus was accounted for by subtracting background from native human serum and normalizing to a high binding serum common to both plates (DT144). DENV, dengue virus; NHS, naive human serum; OD, optical density.

Main Article

TOP